2)
In the abstract: a.
Line 9: "…on inpatient payments (tariff)" -also unclear, because in different countries it could be different systems for inpatient payments. "Health care costs" would be more appropriate. b.
Line 16-18: "The area between the two overlapping distribution curves of inpatient cost at baseline and follow-up (at 3 years) was used to estimate the impact of integrated care on inpatient payments on a population level" -. Practically you estimated the changes in distribution curves by estimating the area between the two overlapping ….and so on. These sentences should be re-formulated c.
Line 22: "…patients with diabetes". You do not use the individual data and you cannot say "patients with diabetes". Do you mean "diabetes population", "the diabetes population admitted to inpatient care"?
3)
Strengths and limitations of this study a.
"With application of this novel method, this study found that the integrated diabetes care was not associated with substantially reduced inpatient payments" -This is neither strength no limitation b.
"The data used in this study depended on the completeness of the coding of diabetes, although there being no systematic change in coding over this time period" -this statement is unclear 4) Introduction a.
The aim of the study is not presented. What questing are you going to answer to fulfill the existing gap? 5) Method a.
Reference is needed line 51 (ECF: 2009 population 160,000, diabetes population 7,790) b.
Line 42-49: "However when using real data to estimate parameters for two normal distributions, it is unlikely that the two curves have the same standard deviation. In our case, the two curves will have crossover points. To overcome this, we have modified the Sarkadi's method as described in supplemental technical appendix". This statement is not correct. In the paper "Sarkadi et.al, 2004" A novel approach used outcome distribution curves to estimate the population-level impact of a public health intervention", there is no assumptions that the two curves have the same standard deviation, contrariwise, the examples were calculated using different standard deviation, see fig 2 page 789. Even if you have two crossover points, the method described in Sarkadi et al is completely applicable and the authors did it correctly presenting in technical appendix. Please, clarify what do you men with the modification of the method.
6)
Results and discussion The authors confuse "health gain" and "impatient payment". Health gain are not the same as "reduced inpatient payments". Why the reduction in impatient payment can be regarded as health gain? Some hypotheses behind that?
Introduction
The trial referred in the introduction (reference 7) is incorrectly interpreted: "showed no impact on outcomes". Only the combined primary end point was insignificant but secondary outcomes such as glycaemic control and cholesterol control were significant. However the actual incremental benefit seems minimal. May be rephrase the sentence for clarity.
No clear justification or reference stated why cluster RCT are not appropriate for evaluation of such services.
Methods
Please clarify what is meant by "There is no major hospital, falling within 4 major hospital catchment areas".
It is unclear why only impact on inpatient cost is assessed. If the aim was to assess the inpatient cost only then the conclusion the care model is not comparatively beneficial cannot be derived from the data presented.
I am unable to critique the analysis as I do not have the expertise or knowledge of the techniques used.
Results
Findings suggest in one age group there was beneficial financial impact, however in Greater Cambridgeshire there was beneficial effect seen in both age groups under consideration. Are the authors aware of any initiative within the hospital or externally in Greater Cambridgeshire that might have resulted in such an observation?
Discussion
The authors say the goal of the integrated care was mostly aimed at reducing referral to outpatient setting. If that is the case why has the modelling only focused on inpatient care costs? 
REVIEWER

GENERAL COMMENTS
The authors must be commended for not only innovating an integrated care approach for type 2 diabetes patients, but also seeking an innovative population-level approach for inference about the relative impact of the Diabetes Integrated Care Initiative (DICI) on inpatient care cost.
This is an important estimate to report in a reliable manner to decision-makers considering integrated care --especially so in recent years, given the increasing majority that inpatient costs take among total diabetes-associated expenditures in the NHS (using Kanavos, van den Aardweg & Schurer, 2012 as a reference). With this context, the authors are to be encouraged to make their findings' conclusions more reproducible via major (yet crucial) revisions to their analysis, so their design and integrated care initiative's efforts may come to fully reliable use by stakeholders. I outline these needed changes below, after outlining key references. Comment: This is a very interesting work aims to estimate the outcomes of a re-structured health care services for diabetes patients at population level. The topic is very important since health care provider do many efforts to optimize health care services in order to improve health outcomes and decrease societal costs. That is why any development of evaluation methodology of such kind of intervention contribute to the literature.
However, there are some areas of the manuscript that would benefit from revision as noted below. Overall It is necessary to define what kind of outcomes are subject for the analysis: societal costs/health care costs/inpatient care costs/health gain. The clear aim of the study should be presented.
Response: Thank you for the suggestion. We declared the objective of this study in the abstract section (page-2) as "assessed the impact of introducing a community service led diabetes integrated care programme on inpatient payments (tariff) in rural England": this is the component of healthcare costs which are paid for by the local NHS commissioners. We have changed the objective in the abstract to: Few studies have estimated the effect of diabetes integrated care at a population level. We have assessed the impact of introducing a community service led diabetes integrated care programme on commissioner payments (tariff) for inpatient care in rural England. We have also changed the introduction last section to: "Under the English National Health Service (NHS), public inpatient care is paid for from taxation through local commissioners. These payments do not generally cover the hospital costs of inpatients with diabetes [10], but can provide an NHS commissioner perspective that reflects both acuity and complexity, beyond eg length of stay. We have now used the Sarkadi approach to assess whether any changes in population based commissioner inpatient payment data occurred during a diabetes integrated care intervention by viewing the level and distribution of commissioner inpatient payments in the population as the unit of interest"
1) The title of the manuscript "Population-level impact of diabetes integrated care on payments for inpatient care among people with type 2 diabetes in Cambridgeshire" is confusing. If you say "payment" -what do you mean? From the manuscript, the reader can understand that the authors mean "tariff". Payment can be also "out of pocket" costs, etc. I suggest to use other terms, such as "health care costs for impatient care", "societal costs for impatient care"
Response: We thank the reviewer for alerting us to this possible confusion. These are not costs as we have previously shown that Government NHS payments for inpatients with diabetes do not cover the associated inpatient costs. We have not used the word tariff as this could also mean user or commissioner payment. We have therefore changed this to 'commissioner' payments and defined this term in the text. Change to:
"Population-level impact of diabetes integrated care on commissioner payments for inpatient care among people with type 2 diabetes in Cambridgeshire"
2) In the abstract: a. Line 9: "-on inpatient payments (tariff)" -also unclear, because in different countries it could be different systems for inpatient payments. "Health care costs" would be more appropriate.
Response: As indicated, these are not costs, but payments. We have now changed the objectives to: "Few studies have estimated the effect of diabetes integrated care at a population level. We have assessed the impact of introducing a community service led diabetes integrated care programme on commissioner payments (tariff) for inpatient care in rural England."
b. Line 16-18: "The area between the two overlapping distribution curves of inpatient cost at baseline and follow-up (at 3 years) was used to estimate the impact of integrated care on inpatient payments on a population level" -. Practically you estimated the changes in distribution curves by estimating the area between the two overlapping -.and so on. These sentences should be reformulated
Response: Apologies, but we do not understand this comment. The area under the curve here is the sum of the inpatient payments over the time period (calculus). The area under the curve is independent of the distribution curve itself-we could have had a greater or lesser peak, with a lesser or greater range, but the sum of payments would be the same. We hope this helps. We have replaced the section as follows and hope this helps: "Commissioner data was provided by the local authority. The difference in area between the two overlapping distribution curves of inpatient payments at baseline and follow-up (at 3 years) was used to estimate the effect of integrated care on commissioner inpatient payments on a population level." c. Line 22: "-patients with diabetes". You do not use the individual data and you cannot say "patients with diabetes". Do you mean "diabetes population", "the diabetes population admitted to inpatient care"?
Response: The revision has been made as suggested.
3) Strengths and limitations of this study a. "With application of this novel method, this study found that the integrated diabetes care was not associated with substantially reduced inpatient payments" -This is neither strength no limitation
Response: The statement has been removed as suggested.
b. "The data used in this study depended on the completeness of the coding of diabetes, although there being no systematic change in coding over this time period" -this statement is unclear
Response: The payment data used in this study is electronic health record (HER) data, the quality of which relies mainly on the completeness of the coding. In England, the completeness of coding for diabetes has generally improved since diabetes QOF indicators were introduced in 2004. In most studies using HER data, the coding issue is usually clarified as a potential systematic error. In this study period, there was no systematic change introduced, so this statement was made to clarify the situation. We have changed the statement to "The data used in this study depended upon the completeness of the coding for diabetes in the GP records. The impact of this potential ascertainment bias should have been steady as no systematic change in coding should have occurred over this time period" 4) Introduction a. The aim of the study is not presented. What questing are you going to answer to fulfill the existing gap?
Response: We have amended the end of the last paragraph in the introduction which hopefully clarifies the issue: "Under the English National Health Service (NHS), public inpatient care is paid for from taxation through local commissioners. These payments do not generally cover the hospital costs of inpatients with diabetes [10], but can provide an NHS commissioner perspective that reflects both acuity and complexity, beyond eg length of stay. We have now used the Sarkadi approach to assess whether any changes in population based commissioner inpatient payment data occurred during a diabetes integrated care intervention by viewing the level and distribution of commissioner inpatient payments in the population as the unit of interest" 5) Method a. Reference is needed line 51 (ECF: 2009 population 160,000, diabetes population 7,790)
Response: The reference has been added as suggested.
b. Line 42-49: "However when using real data to estimate parameters for two normal distributions, it is unlikely that the two curves have the same standard deviation. In our case, the two curves will have crossover points. To overcome this, we have modified the Sarkadi's method as described in supplemental technical appendix". This statement is not correct. In the paper "Sarkadi et.al, 2004" A novel approach used outcome distribution curves to estimate the population level impact of a public health intervention", there is no assumptions that the two curves have the same standard deviation, contrariwise, the examples were calculated using different standard deviation, see fig 2 page 789. Even if you have two crossover points, the method described in Sarkadi et al is completely applicable and the authors did it correctly presenting in technical appendix. Please, clarify what do you men with the modification of the method.
Response: Thanks for pointing this out. I agree with the reviewer that in Sarkadi's paper, they have shown examples for the case when the two curves have different standard deviations (SD). However, the method only works when the follow-up group have lower mean, and either higher SD or the same SD. Our modification was to address the case when the follow-up group have lower mean, but lower SD also. In this case, there will be two crossover points, both of which are higher than the follow-up mean. Our modification corresponds to choosing the lambda value as the smaller of the two solutions of (A1:3) from the technical appendix, when the SD is lower in the follow up group. This is different from the other case when SD higher is in the follow-up group, the larger of the two solutions for lambda should be chosen. This was not explicitly described in in Sarkadi et al.
We have changed the descriptions for the modification to make this clear.
6) Results and discussion
The authors confuse "health gain" and "impatient payment". Health gain are not the same as "reduced inpatient payments". Why the reduction in impatient payment can be regarded as health gain? Some hypotheses behind that?
Response: Reduction in healthcare payments under the NHS allows the liberated public funds to be used elsewhere to achieve a gain in health. We now specify this in the methods:
The reduction in commissioner payments is seen as a 'health gain', as under the NHS, such liberation of public funds can be used elsewhere to achieve a gain in health.
Reviewer Please leave your comments for the authors below The authors have attempted to quantify the health gain achieved from an integrated diabetes service implemented in East Cambridgeshire and Fenland. Authors acknowledge the difficulties posed in evaluating such services and have utilised a novel method to assess the benefit of the service, though the assessment is limited by utilising inpatient cost. Introduction The trial referred in the introduction (reference 7) is incorrectly interpreted: "showed no impact on outcomes". Only the combined primary end point was insignificant but secondary outcomes such as glycaemic control and cholesterol control were significant. However the actual incremental benefit seems minimal. May be rephrase the sentence for clarity. Response: The statement has been changed as "One randomised trial of an intermediate care service achieved minimal actual incremental benefit [7] ".
Response: Thank you, we have changed this sentence to "By their nature, randomised controlled trials are difficult to utilise when assessing the impact of a complete system change at a population level"
Methods Please clarify what is meant by "There is no major hospital, falling within 4 major hospital catchment areas". Response:
The geographical area has no major hospital (with eg an emergency department, acute medical wards), as these lie in neighbouring areas. Revised to: "There is no local major hospital (with eg an emergency department), falling within the catchment areas of 4 hospitals outside of the area" It is unclear why only impact on inpatient cost is assessed. If the aim was to assess the inpatient cost only then the conclusion the care model is not comparatively beneficial cannot be derived from the data presented.
Response: We concurrently assessed the impact on metabolic control and hospitalisation and found no impact (reference 6). We have now obtained the tariff (commissioner payment data), which can sometimes show benefit as it reflects different components beyond hospitalisation (yes/no) and length of stay such as complexity and acuity of admissions. We have now added in the methods: We have previously reported no impact on metabolic control or hospitalisation rates in spite of full implementation of the service (reference 6).
No changes made
Results Findings suggest in one age group there was beneficial financial impact, however in Greater Cambridgeshire there was beneficial effect seen in both age groups under consideration. Are the authors aware of any initiative within the hospital or externally in Greater Cambridgeshire that might have resulted in such an observation?
Response: Yes, local hospital diabetes services had continuous quality improvement programmes, however, we can not necessarily attribute such changes to this. We have added: '…although each hospital based service would have continued with its own internal service developments.'
Discussion
The authors say the goal of the integrated care was mostly aimed at reducing referral to outpatient setting. If that is the case why has the modelling only focused on inpatient care costs?
Response: Yes, we agreed that the goal could be both at inpatient and outpatient care. Due to the access of data, we could not evaluate the outpatient care in this study, we have admitted this in the Limitation section. The goal was not reducing referrals, this was the prior philosophy, before the wider programme was introduced. We have therefore changed the text to: This philosophy, rather than progressing to truly integrated services carried through the intervention period, albeit as part of a wider programme that included 'vertical integration' developments. It was perhaps to be expected that attempts at creating such greater 'vertical' integration in information management, clinical governance, budget and overall management were agreed but not implemented, actions more achievable within a single organization. In addition, as above, we have already published on the wider changes (reference 6) where we described the impact on metabolic control and hospitalisation. As above, tariff data provides information on acuity and complexity beyond hospitalisation and length of stay.
Reviewer: 3 Reviewer Name: Dr Lauren Rodgers Institution and Country: University of Exeter Medical School, UK Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below This paper reviews the impact of integrated care on inpatient tariffs in rural England. There are clarifications in the analysis and reporting of the data which should be addressed prior to publication. Specific comments 1. Page 3. Bullet 2 -should be "negative values were raised". Bullet 4 does not make sense. Response: We have changed the text to:
The 'health gain' in the revised method was clearly defined with a formulated algorithm of evaluation, which broadened the utilization scenarios especially when negative values were raised.
2.
Methods/Results/ Table 1/Table 2 . No N is provided for any of the regions or age groups. Sample size is of huge importance when analysing and interpreting results. This omission must be corrected.
Response: Due to the limitation in data access, there was no personal identification to identify the repeated records occurred by the same person. As all analyses were record based study. The number of hospitalised records were listed in the supplemental table 1. We now include the numbers within table 1 and dropped supplemental table 1 3.
Methods paragraph 2, page 5. Are code lists to be published? Reference error on line 36.
Response: The code is available for review and will be shared to readers upon request after publication. The reference error has been corrected.
4.
Methods paragraph 3, page 5. Why are baseline and follow-up sampled separately in the bootstrap? Surely they are linked data? Please justify. Does the second sentence imply that there are different numbers of baseline and follow-up data here? Please indicate if this is the case and provide details on how much data are missing and why.
Response: We thank the referee for highlighting this area of possible confusion. As previously described, the records are based upon anonymised, rather than individual, data. As a result, it was not possible to match samples for the baseline and follow-up analyses. However, using the method in the manuscript, the population-wide changes could be evaluated based upon the hypothesis that the baseline and follow-up inpatient payments occurred within the same diabetes population. We have clarified this in the Figure legend for Supplemental Figure 2 as: "The health payment gain (impact) was defined as percentage of people with type 2 diabetes and hospital admission having reduced heath payments after 3 years of diabetes integrated care at a population level. Distributions of the impact were approximated by bootstrapping. Subjects and their associated payments were selected by random resampling with replacement from the original data 10000 times, and the impact was calculated in each resampled dataset. The dashed red line shows the impact in the original data. The bootstrap p value was calculated by comparing the impact estimated in the resampled data to 0 (indicated by the solid red line; null hypothesis H0: impact<=0, and alternative hypothesis H1: impact>0; P = [Percentage with impact <= 0])".
5.
Results page 6. What are patients grouped above and below 70? Do the results differ for different cut-offs? Reference to Figure- Response: Age as a common, and significant confounder, was tackled by stratification analysis in this study. 70 was the median of patients generated the inpatient care record, we now highlight this as the reason for this age for dichotomisation. Sorry for the typo. There is no Figure-2 in the main text. The age-stratified results were both refer to Figure-1 and supplemental Figure-2 . The typo 'iss' has been corrected to 'is' as suggested. We have added a sentence in the methods: "Age data were provided allowing analyses to be undertaken above and below the median age (70 years) to assess any related variation".
6.
Results Table 2 . Results in table are not presented as percentages as per the label. Please reduce the decimal places once converted to percentages to two at most.
7.
Supplementary Figure 2 . The label mentions percentage of people but histograms are of frequency. What does the dashed line represent in the plots? Similar, why is there a line at 0?
Response: The figure legend of supplemental figure 2 has been updated as below "The health payment gain (impact) was defined as percentage of people with type 2 diabetes and hospital admission having reduced heath payments after 3 years of diabetes integrated care at a population level. Distributions of the impact were approximated by bootstrapping. Subjects and their associated payments were selected by random resampling with replacement from the original data 10000 times, and the impact was calculated in each resampled dataset. The dashed red line shows the impact in the original data. The bootstrap p value was calculated by comparing the impact estimated in the resampled data to 0 (indicated by the solid red line; null hypothesis H0: impact<=0, and alternative hypothesis H1: impact>0; P = [Percentage with impact <= 0])".
8.
Discussion page 7. It is not clear how the results translate into costs and investment amounts. What would constitute a 'good' outcome compared to the results obtained?
Response: We have now described how commissioner savings under the NHS can be used elsewhere to benefit the local health economy. We have stated this on page 10 as "The latest changes in commissioning in the English NHS, with emphasis on the need to consider 'Any qualified Provider' in service delivery, and associated market procurement approaches, could well impair the quality of diabetes care while increasing overall cost, if the experience here is reproduced elsewhere. ". 9.
Page 14. Comment: The authors must be commended for not only innovating an integrated care approach for type 2 diabetes patients, but also seeking an innovative population-level approach for inference about the relative impact of the Diabetes Integrated Care Initiative (DICI) on inpatient care cost.
Response: This is an important estimate to report in a reliable manner to decision-makers considering integrated care --especially so in recent years, given the increasing majority that inpatient costs take among total diabetes-associated expenditures in the NHS (using Kanavos, van den Aardweg & Schurer, 2012 as a reference).
With this context, the authors are to be encouraged to make their findings' conclusions more reproducible via major (yet crucial) revisions to their analysis, so their design and integrated care initiative's efforts may come to fully reliable use by stakeholders. I outline these needed changes below, after outlining key references. Response: We thank the referee for his comments. References Comment: For more on UK's NHS cost burden getting substantial contribution (>60%) from inpatient costs (albeit for both types of diabetes), placed in context within other EU-affiliated nations, see Kanavos, van den Aardweg & Schurer, 2012 Response: We thank the reviewer for pointing out G-computation and other related methods to control for confounding and for evaluating the impact of system-wide interventions. We have attempted to implement the G-computation approach, and this has not changed our findings. We now state this in the last paragraph of the results section. As a matter of fact, the present study has been performed under the assumption that baseline and follow-up inpatient payments occurred in the same diabetes population, and so the problem of confounding factors seems less critical in this study.
Comment: For more on increasing statistical power for within-system changes in inpatient costs, by incorporating correlation between baseline and followup cost distributions, consult textbooks covering multivariate data methods for Gaussian and other generalized linear model outcomes (e.g., Fitzmaurice, Laird & Ware on longitudinal data, Goldstein on multilevel data, among others)
Response: Unfortunately, we are restricted by data access and there are no further co-variables besides sample age available for multivariable analyses. We have admitted this in the limitations section.
Major revisions needed a. replace the poorly-approximating normal/Gaussian distribution for inpatient cost with one more appropriate to the right-skewed costs often cited in this literature (e.g., gamma, log-normal or some finite mixture thereof), readily implemented using R software as done in the current writeup; unlike Sarkadi et al's Eyberg Childe Behavior Inventory, your outcome has not been summed or aggregated in any manner that helps you appeal to law of large number approximations (at least as currently described). The medians and interquartile ranges reported in Table 1 seem consistent with rightskewed cost distributions, afterall.
Response: Thank you for the suggestion. We have applied the gamma distribution and log-normal distribution in our data. However, there was no significant improvement in fitting the data distributions observed by applying these distributions. We have described these attempts in the last paragraph of the results section.
b. do not hamper your statistical power by failing to leverage the likely positive dependence between inpatient cost distributions at baseline and followup; even if your available data in NHS's Secondary Uses Service (SUS) portal does not allow individual-level, some aggregate measures of repeatinpatient-admissions in a given time period would provide a range of plausible values to consider when reporting estimates. To underscore why this is crucial, bear in mind that the apparent lack of impact may be in fact due to underpowered statistical analysis --one that implicitly assumes an untenable proposition for a 'closed' health care system: patients never require inpatient care again after having it once, in other words, costs at the two time-points are completely independent of one another. At the very least, you will provide a range for other systems' decision-makers to consider relative to their populations' propensity for repeating inpatient care in a similar time period.
Response: Thank you for this good suggestion. We have added this statement in the discussion section.
c. recognize that the stated objectives' use of the term 'impact' necessitates some form of causal inference, as outlined in the invited commentary on Sarkedi et al's population-level impact analysis approach; authors need to explicitly acknowledge that current analysis (even after meeting revisions a & b) may still yield findings subject to confounding bias --the 'impact' may only reflect unmeasured changes in the DICI and 'control' areas respectively, rather that DICI itself as the DICI care model was not randomly assigned...you want to present estimates that have a causal interpretation (at least under the unverifiable assumption of no unmeasured confounders).
It's encouraging to see the authors address a slew of much-needed revisions requested by the four original reviewers. All changes to this point, ranging from efforts to sharpen terminology, meet emerging standards (e.g., Consolidated Health Economic Evaluation Reporting Standards, CHEERS) or elaborate on data/study limitationshave been made in the spirit of improving the research presentation via peer review. I'm eager to see these appropriatelypresented findings reach publication. <p> For this to take place, however, I do see some minor revisions required still at this stage: a. Clearly state that lack of evidence of intervention effects does not equate to evidence that intervention lacks any effect whatsoever, it merely speaks to lack of statistical power or shortfall of information that a more suitably designed study may well detect. In short, explicitly revise the article to address the following: <p> (i) Appropriately caveat your 'negative' findings as being due to data limitations...if you had longitudinal data, you would have greater power to detect between-group differences from baseline to followup (attributable to the intervention, DICI) as the fraction of individual patients who incurred "costs"/"payments" in both periods could serve as their own internal 'controls' regardless of intervention status; more bluntly, any analysis must recognize that these 'repeat-incurrers' of payments provide redundant information, such that the method of Sarkadi et al. --as employed by Feldman et al., (when applying a bootstrap that explicitly ignores this redundancy) by resampling strictly within each timepoint --is a mis-application of tools despite the best of intention. It cannot be ruled out that this study's findings are inconclusive simply by dint of failing to exploit additional statistical power by explicitly accounting for this (likely nonnegligible) fraction who could serve as their own controls. Stated in terms that someone who presumes the null hypothesis of no difference in outcomes might, such miss-application may inadvertently increase the false positive rate: if, in fact, the naive application of Sarkadi et al's method to substantially dependent data with considerable zero-inflation does lead to an inflated Type I 'false positive' error, the observed p-values for certain NHS regions might be considered in a distinctly different light.
<p>
(ii) Quantify within a main-article table the degree to which your inconclusive findings change when presuming a plausible range of baseline-to-followup dependence or correlation --while it's understandable that (without longitudinal links) you cannot empirically estimate this dependence, you can call upon similar "payment" data that you can access, estimate its measures of dependence (e.g., Pearson's correlation coefficient, with a Fisher's z-transform-based suitably-chose confidence interval) and report the extent to which your findings change under simulated bootstrapped samples that, in all other respects, match your observed data.
(iii) Quantify the extent to which alternate distribution assumptions (e.g., gamma or log-normal) did not make improvement in fitting the data by actually reporting the estimated goodness-of-fit measures for the normal distribution versus these alternatives. It may be done in a footnote of the table or parenthetically in the narrative as space limitations dictate. <p> b. In addition to stating how findings in alternate analyses were similar to those reported in primary analyses (such as in a., gauging how inconclusive findings may change once plausibly assuming that some fraction of patients incur cost at both baseline and followup), you should quantify how different from your current (implicit) assumptions a reasonable alternative situation would have to be (as might be done in G-computation) in order for the findings to become conclusive one way (intervention worse than standard care) or the other (intervention better than standard care); this is often called a "tipping-point" analysis, as frequently employed in the missing data literature. As the data have been anonymized, apart from age, and not linked longitudinally, you need only specify the extremes of a plausible range in addition to those separate re-analyses you've already done and reported in your response as having similar results; the minor revision that's crucial (for sake of both rigor and reproducibility) is supplying these quantities in the results table or a footnote thereto. <p> c. clear up the confusion in terminology regarding "tariff"/"cost"/"payment" with an up-front definition of terms AND consistent use thereafter so that a motivated reader might avoid the confusion that the original reviewers (and to some extent, those on this second review) might encounter. <p> With these minor changes, the investigative team will have refined their manuscript to the standards of rigor and reproducibility expected of BMJ Open articles, in my opinion.
